Vmax™ Express has a more rapid doubling time and generates greater biomass to yield larger amounts of soluble recombinant protein.
Heidelberg, Germany, September 20, 2017 / B3C newswire / -- BioCat GmbH in Heidelberg, Germany, announced today a distribution partnership with SGI-DNA, a Synthetic Genomics Inc. company in San Diego, CA, USA, for Vmax™ Express, a rationally engineered bacterial host organism that offers a significant improvement in recombinant protein expression.
Under the terms of the agreement, BioCat, a specialized distributor with a strong focus on life science research, will promote, market, sell, and support Vmax™ Express cells and media to customers across continental Europe. To ensure fast delivery of these products, BioCat is maintaining inventory of Vmax™ Express at their facility in Heidelberg.
To allow a seamless transition from commonly used E. coli-based systems, Vmax™ Express uses a similar workflow and is compatible with commonly used plasmids, antibiotics, and growth media. However, unlike other bacterial expression systems, Vmax™ Express has a more rapid doubling time and generates greater amounts biomass to yield larger amounts of soluble recombinant protein.
Vmax™ Express offers several advantages over E. coli, including:
Additional product information is available at biocat.com/partners/sgi-dna
Dr. Michael Ehret, CEO at BioCat said, “The partnership with SGI-DNA complements our existing protein expression portfolio with a highly advanced bacterial host organism and strengthens our ability to meet the growing demand for tools enabling the efficient production of recombinant proteins.”
Nathan Wood, President at SGI-DNA added, “BioCat is well known for offering high-quality research reagents, cutting-edge technologies and provides excellent technical support, making them an ideal distribution partner for our next-generation protein expression platform, Vmax™ Express.”
BioCat GmbH is a privately held company based in Heidelberg, Germany. The company supplies life scientists in academia and pharma/biotech with innovative and high-quality research kits and reagents in the fields of genomics, protein analysis and expression, and cell biology. BioCat is dedicated to driving scientific discoveries by providing solutions and support to speed research and simplify workflows.
SGI-DNA, a wholly owned subsidiary of Synthetic Genomics Inc., provides genomic solutions to advance scientific discovery. SGI-DNA’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. SGI-DNA’s genomic services include whole genome sequencing, DNA synthesis, library design, bioinformatics, cell engineering, and plasmid DNA cloning and purification. SGI-DNA’s reagents include a complete suite of Gibson Assembly® and Site Directed Mutagenesis kits as well as optimized cell lines. To further enable the synthetic biology workflow, SGI-DNA offers the BioXp™ 3200 System. This fully automated genomics workstation allows the creation of double-stranded DNA fragments, automated cloning, as well as Next-Generation Sequencing DNA library preparation. Building on scientific breakthroughs from J. Craig Venter, Hamilton Smith, Clyde Hutchison, Daniel Gibson and their teams, SGI-DNA is committed to reducing barriers associated with synthetic biology.
About Synthetic Genomics
Synthetic Genomics Inc. is a leader in the field of synthetic biology, advancing genomics to better life. Synthetic Genomics applies its intellectual property in this rapidly evolving field to design and build biological systems solving global sustainability challenges. Synthetic Genomics’ core technology enables two connected genome-writing businesses: engineering advantaged cell platforms and printing biological components. The company’s subsidiary, SGI-DNA, is revolutionizing science and medicine by automating next-generation genomic solutions for life sciences. Synthetic Genomics applies its integrated synthetic biology and engineering capabilities to create and commercialize novel solutions and transform existing products. Synthetic Genomics is reinventing bio-based production by improving existing production systems and developing novel, optimized production hosts. The company develops its products and solutions, typically in partnership with leading global organizations, across a variety of industries including sustainable bio-fuels, sustainable crops, nutritional supplements, vaccines, biotherapeutics and transplantable organs.
Im Neuenheimer Feld 584
Tel.: +49 (0) 6221 71415 16
Fax: +49 (0) 6221 71415 29
Liz Liner, Synthetic Genomics
Corporate Communications and Media
Ian Stone, Canale Communications